WallStSmart
ARTL

Artelo Biosciences Inc

NASDAQ: ARTL · HEALTHCARE · BIOTECHNOLOGY

$2.40
-3.50% today

Updated 2026-06-05

Market cap
$5.05M
P/E ratio
P/S ratio
EPS (TTM)
$-29.01
Dividend yield
52W range
$1 – $86
Volume
3.9M

Artelo Biosciences Inc (ARTL) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201420152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Gross margin
R&D$1.25M$1.25M$1.25M$1.25M$1.09M$1.92M$2.84M$4.32M$5.70M$5.99M$5.42M
SG&A$15269.00$15241.00$29690.00$232789.00$1.09M$2.12M$2.77M$4.60M$5.96M$4.23M$4.12M$5.98M
Operating income$-15269.00$-15241.00$-29690.00$-232789.00$-2.34M$-3.21M$-4.69M$-7.44M$-10.29M$-9.93M$-10.11M$-11.40M
Operating margin
EBITDA$-15269.00$-15241.00$-29690.00$-232789.00$-2.34M$-4.22M$-4.69M$-7.44M$-10.08M$-9.29M$-9.83M$-12.54M
EBITDA margin
EBIT$-15269.00$-15241.00$-29690.00$-232789.00$-2.34M$-4.22M$-4.69M$-7.44M$-10.29M$-9.93M$-10.11M$-12.69M
Interest expense$0.00$0.00$0.00$2100.00$0.00$0.00$0.00$0.00$5000.00$0.00$0.00$194000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-15269.00$-15241.00$-29690.00$-234889.00$-2.34M$-2.17M$-4.66M$-7.44M$-10.08M$-9.29M$-9.83M$-12.88M
Net income growth (YoY)+0.2%-94.8%-691.1%-897.7%+7.3%-114.3%-59.8%-35.6%+7.9%-5.8%-31.1%
Profit margin

Frequently asked questions

How much free cash flow does ARTL generate?

ARTL produced $-8.52M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ARTL's balance sheet healthy?

ARTL holds $600000.00 in cash and equivalents against — in long-term debt, on $-1.27M of shareholder equity. That debt is best read against the cash flow the business throws off each year.